MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Ketogenic Diet and Motor Outcomes in Parkinson’s Disease: A Meta-analysis of Randomized Trials

A. Fornari Caprara, J. Pitton Rissardo, J. Patino, A. Mcgarry, I. Walker (Camden, USA)

Meeting: 2026 International Congress

Keywords: Parkinson’s

Category: Parkinson’s Disease: Pharmacology and Medical Management

Objective: To evaluate the effects of ketogenic diet (KD) interventions on motor outcomes and adverse events in Parkinson’s disease (PD).

Background: Metabolic therapies such as KD have been proposed to improve mitochondrial efficiency and reduce oxidative stress in PD, potentially improving motor symptoms; however, existing trials report variable results and lack consensus on clinical impact and safety.

Method: A meta-analysis of PubMed-indexed randomized controlled trials evaluating KD in PD was performed. Extracted data included MDS-UPDRS-III and MDS-UPDRS-II in the ON state, weight, metabolic biomarkers, and adverse event risks. Effect sizes were calculated as mean differences (MD) or relative risks (RR) using inverse-variance and Mantel-Haenszel methods, applying random-effects models when appropriate.

Results: Five trials involving 129 participants were analyzed. KD did not significantly improve MDS-UPDRS-III (MD 0.97, 95% CI −1.99 to 3.92) [Figure 1] or MDS-UPDRS-II (MD −1.45, 95% CI −3.12 to 0.23) [Figure 2]. No consistent effects were observed for weight (MD 0.19, 95% CI −1.34 to 1.72) [Figure 3], glucose (MD 0.54, 95% CI −0.02 to 1.10), or triglycerides (MD 0.15, 95% CI −0.24 to 0.55). A significant reduction in A1c (MD −0.33, 95% CI −0.61 to −0.05) and an increase in total cholesterol (MD 1.57, 95% CI 1.19 to 1.95) were observed. Adverse event rates were comparable between KD and control groups, with nonsignificant relative risks for constipation (RR 3.80, 95% CI 0.18–80.57), fatigue (RR 0.73, 95% CI 0.10–5.22), and dizziness (RR 0.88, 95% CI 0.14–5.60).

Conclusion: KD did not produce significant improvements in motor function. Metabolic effects were minimal, and adverse events were comparable to controls. Larger, longer-duration studies are needed to clarify the therapeutic role of KD in PD.

Figure 1. Pooled MD of motor outcomes.

Figure 1. Pooled MD of motor outcomes.

Figure 2. Pooled MD of UPDRS-II.

Figure 2. Pooled MD of UPDRS-II.

Figure 3. Pooled MD of weight change.

Figure 3. Pooled MD of weight change.

To cite this abstract in AMA style:

A. Fornari Caprara, J. Pitton Rissardo, J. Patino, A. Mcgarry, I. Walker. Ketogenic Diet and Motor Outcomes in Parkinson’s Disease: A Meta-analysis of Randomized Trials [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/ketogenic-diet-and-motor-outcomes-in-parkinsons-disease-a-meta-analysis-of-randomized-trials/. Accessed October 1, 2026.
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/ketogenic-diet-and-motor-outcomes-in-parkinsons-disease-a-meta-analysis-of-randomized-trials/

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley